Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively-Reference-Cited by-同舟云学术

Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively

Published:2018-03-29 Issue:13 Volume:23 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Adlhoch Cornelia¹,Snacken René¹,Melidou Angeliki²,Ionescu Silviu¹,Penttinen Pasi¹,

Affiliation:

1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

2. Microbiology Department, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

Abstract

We use surveillance data to describe influenza A and B virus circulation over two consecutive seasons with excess all-cause mortality in Europe, especially in people aged 60 years and older. Influenza A(H3N2) virus dominated in 2016/17 and B/Yamagata in 2017/18. The latter season was prolonged with positivity rates above 50% among sentinel detections for at least 12 weeks. With a current west–east geographical spread, high influenza activity might still be expected in eastern Europe.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference19 articles.

1. Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017.;Vestergaard;Euro Surveill,2017

2. Influenza activity in Europe during eight seasons (1999-2007): an evaluation of the indicators used to measure activity and an assessment of the timing, length and course of peak activity (spread) across Europe.;Paget;BMC Infect Dis,2007

3. Implementation of the community network of reference laboratories for human influenza in Europe.;Meijer;J Clin Virol,2005

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IRF7-deficient MDCK cell based on CRISPR/Cas9 technology for enhancing influenza virus replication and improving vaccine production;PeerJ;2022-09-21

2. Cross-Protection Induced by Virus-like Particles Derived from the Influenza B Virus;Biomedicines;2022-07-06

3. Epidemiological and virological surveillance of influenza viruses in China during 2020–2021;Infectious Diseases of Poverty;2022-06-29

4. Influenza B: Prospects for the Development of Cross-Protective Vaccines;Viruses;2022-06-17

5. Epidemiological and Clinical Characteristics of Influenza Outbreaks Among Children in Chongqing, China;Frontiers in Public Health;2022-04-15